Industry Reports Services Press Release
  •   Blogs
  • Contact us About us

    Asia Pacific Cannabidiol (CBD) Market Forecast 2027 by Application (Anxiety/Stress, Sleep/Insomnia. Chronic Pain, Migraine, Skin Care, Seizures, Joint Pain & Inflammation, Neurological Conditions), Product (Oil, Tinctures, Suppository, Transdermal Patches, Isolates, Tablet, Capsules, Vape Oil, Creams And Roll-On), Route of Administration (Oral, Topical, Inhalation, Transdermal Patches, Rectal, Sublingual), Source (Marijuana, Hemp), Distribution Channel (Online, Offline {Hospital Pharmacies, Retail Stores}), Research Report, Country Outlook (Japan, Australia, New Zealand, Thailand), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
    Published Date: May 2021   |   Report ID: GR1824   |   Delivery: PDF  Request Free Sample

    Asia Pacific CBD Market size exceeded USD 129.8 million in 2020 and is predicted to grow at more than 35.2% CAGR from 2021 to 2027.

    Cannabidiol is used for medical conditions such as anxiety, seizures, muscle disorders, and Parkinson’s disease among other conditions. In the recent years, cannabidiol based products have been sold as supplements in many countries such as the Japan, Australia, Thailand, and others. In addition, it is claimed to have additional benefits for several ailments without having any negative effects. For instance, CBD has been studied for its pain relieving effect in individuals with chronic pain and neuropathic, especially when the patients are unaffected by other treatments.

    Asia Pacific Cannabidiol (CBD) Market, 2021 & 2027 (USD Mn)

    Get more details on this report - Request Free Sample PDF

    Further, as of now there are few cannabidiol based medications available in the market such as Epidiolex and Sativex, among others. These products help in treating multiple sclerosis (MS) symptoms as well as for the treatment of acute neuropathic-associated cancer pain. Thus, high potential applications of cannabidiol for various ailments will create steady opportunities in the market.

    Asia Pacific Market, By Product

    The oil segment revenue was over USD 31.4 million in 2020. Adoption of oils for varied ailments due to its efficacy and ease of use will drive the oils segment revenue. Further, CBD products including oils is legal according to laws in Japan.

    CBD oil products in the country are mainly imported and used mostly for cosmetics, health products or food, dietary supplements, pet snacks and for CBD electronic cigarettes, among others. For instance, in February 2020, Hiro International launch a THC-free CBD oil product mainly known as Orange CBD. The product is an alternative to hemp-based cannabidiol.

     Asia Pacific Market, By Application

    The chronic pain segment size will cross USD 570 million by 2027. The increased adoption of CBD products such as oils and capsules among others for suppressing chronic pain is one of the major factors supplementing the market growth. For instance, according to the Australian Institute of Health and Welfare (AIHW), chronic pain is a common and complex condition characterized by persistent pain experienced on most days of the week, affecting 1 in 5 Australians aged 45 and over.

    Asia Pacific Market, By Route of Administration

    The oral route of administration dominated a market share of 53.1% in 2020 due to increased usage of oral CBD products such as oils, tinctures, capsules, and tablets. In addition, oral drug launches for treating various syndrome such as Lennox-Gastaut syndrome and Dravet syndrome will propel the market demand.

     Asia Pacific Market, By Source

    The hemp-derived source segment will observe significant growth of 35.5% during the forecast period. The use of hemp-derived CBD products is increasing rapidly owing to its anti-aging, antioxidant, and anti-inflammatory properties. Thus, various industries such as pharmaceuticals, nutraceuticals, and food and beverages are developing CBD-derived products for health and wellness purposes. Furthermore, several countries such as China and Australia among others support the cultivation of hemp that would further create profitable opportunities in the industry.

     Asia Pacific Market, By Distribution Channel

    The offline segment is estimated to reach USD 1 billion by 2027 impelled by the increased sales in retail stores. Also, the cannabidiol derived nutritional supplements are being marketed in food & health stores. Furthermore, after the legalization of CBD products in various Asia Pacific countries, the avenues for supplying these products significantly increased due to the expanding consumer pool.

     Asia Pacific Market, By Country

    Australia cannabidiol market size valued at USD 30.5 million in 2020 and is poised to show considerable CAGR of 35.4% through 2027. High growth rate is due to rising government support and legalization of CBD products in the country. For instance, in September 2020, Australian government announced plan to reschedule low-dose CBD products that will enable consumers to legally purchase CBD products over the counter (OTC). Furthermore, with increasing prevalence of diseases across the Asia Pacific, the adoption of cannabidiol products has witnessed an exponential growth in the recent years.

     Competitive Industry Landscape

    Key companies operating in the industry are ECOFIBRE, Bod Australia Ltd, MEDLAB CLINICAL, Aurora Cannabis, Cronos Group, and CV Sciences, Inc. among others.

    Frequently Asked Question(FAQ) :

    How much is the Asia Pacific cannabidiol market worth?
    The industry for CBD in Asia Pacific was valued at USD 129.8 million in 2020 and will grow at a CAGR of 35.2% between 2021 and 2027.
    Why will the Asia Pacific cannabidiol segment gain commendable proceeds from oils?
    CBD oils accounted for more than USD 31.4 million of industry revenue in 2020 and will grow owing to rising product adoption due to the ease and efficacy of use.
    What factors will escalate the share of the oral route of administration to the Asia Pacific cannabidiol sector?
    Oral route of administration held a share of 53.1% of the APAC market value in 2020 and will grow due to the rising usage of oral CBD products such as capsules, tinctures, oils, and tablets.
    Why will the CBD industry expand in Australia?
    The industry for cannabidiol in Australia surpassed USD 30.5 million in 2020 and will grow at a CAGR of 35.4% over 2021-2027 driven by surging government support and the legalization of CBD products in the country.

    Get this research report on Asia Pacific Cannabidiol Market customized according to your business requirements.

    report-purchase - logo Buy Now

    Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team


     [email protected]